Virtual Program Agenda
(information subject to change; visit www.thyroid.org for updates)

Content from the ATA 2020 in-person Satellite Symposium cancelled due to COVID-19 has been transitioned into a virtual program. CME and MOC is credit available for one year from initial release date; see below for release dates.

**Personalized Approach to Thyroid Disorders Part 1 (2 hours of content)**
*(Webinar release Date coming soon; Available on-demand for video replay after release date)*

Includes all programming listed here:

**Case Discussions: Decisions on How to Treat Common Benign Thyroid Disorders**
- Pregnancy, Hypothyroidism and Hyperthyroidism
  - Panelists: Maria Papaleontiou (moderator); Elizabeth N. Pearce, Rebecca S. Sippel, Anne R. Cappola, Cari Meinhold Kitahara and Reese W. Randle

**Case Discussions: Decisions on How to Personalize Approach to Thyroid Cancer Diagnosis and Treatment**
- Clinical decision-making in patients with: Microcarcinomas, Low risk tumors and Advanced thyroid cancer
  - Panelists: Maria Papaleontiou (moderator), Ramona Dadu, Jennifer E. Rosen, Susan C. Pitt and Mabel M. Ryder

**Personalized Approach to Thyroid Disorders Part 2 Agenda (2+ hours of content)**
*(Webinar release Date coming soon; Available on-demand for video replay after release date)*

Includes all programming listed here:

**Thyroid Disorders in Pregnancy** (Tim Korevaar)
- Different TSH reference ranges according to ethnicity, BMI, other factors; Impact of autoimmunity in decision to treat; Newborn outcomes

**Hypothyroidism After Thyroidectomy and Autoimmune: Do We Treat It Differently?**
- Thyroid hormone resistance: what is it and how to overcome it, and issues of thyroid hormone conversion and signaling (Douglas Forrest)
  - Addition of T3? (Anne R. Cappola)
  - Surgery as strategy to treat autoimmune thyroid disease, eliminate TPO Abs, and quality of life issues (Rebecca S. Sippel)

**Hyperthyroidism: Personalized Therapeutic Options According to Etiology and Patient Preference**
- RAI and risk of secondary malignancies (Cari Meinhold Kitahara)
  - Role of surgery: when and why (Sarah Oltmann)
  - Use of decision-aids in hyperthyroidism (Susan C. Pitt)

**Initial Approach to Low Risk Thyroid Cancer**
- Use of decision-aids to proceed with active surveillance versus lobectomy versus total thyroidectomy (Reese W. Randle)
  - How does molecular testing help in thyroid nodules when combined with ultrasound characteristics? (Jennifer A. Sipos)

**Approach to Advanced Thyroid Cancer**
- When not to operate in advanced thyroid cancer (Patrick Ha)
  - How does molecular testing inform extent of initial surgery in low risk and high-risk lesions? (Masha Livhits)
  - Molecular-based therapies and redifferentiation trials (Mabel M. Ryder)